Boston Scientific (NYSE:BSX) is looking double its emerging markets presence over the next 2 years as it seeks to catch up with larger competitors like Medtronic (NYSE:MDT), CEO Mike Mahoney told investors in San Francisco today.
Mahoney, speaking at the J.P. Morgan Healthcare Conference, said the company derived about 10% of its total sales from emerging markets in Brazil, Russia, India and China during the 3-months ended Sept. 30, 2014, an 18% increase from the same period in 2013.
Help employers find you! Check out all the jobs and post your resume.
